Question 1

What is the analyst consensus rating for BBOT?

Accepted Answer

The analyst consensus rating for BBOT is "Buy" based on 4 analyst recommendations.

Question 2

What is the average price target for BBOT?

Accepted Answer

The average 12-month price target for BBOT is $23.00, representing an upside of 115.8% from the current price of $10.66.

Question 3

What do analyst ratings mean?

Accepted Answer

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

Question 4

What is a price target?

Accepted Answer

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Date	Analyst	Firm	Action	Rating	Price Target
Jan 9, 2026	Sean McCutcheon	Raymond James	Initiates	Buy	$24.00
Dec 12, 2025	Edmund Ingham	Forbes	Initiates Coverage	Buy	-
Dec 11, 2025	David Nierengarten	Wedbush	Reiterates	Buy	$25.00 → $25.00 +0.00 (0.0%)
Dec 5, 2025	Sean Laaman	Morgan Stanley	Initiates	Buy	$20.00
Nov 25, 2025	David Nierengarten	Wedbush	Reiterates	Buy	$25.00 → $25.00 +0.00 (0.0%)

BridgeBio Oncology Therapeutics (BBOT) Stock Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest BBOT Analyst Ratings & Recommendations